Cytokinetics (CYTK) EVP sells 26K shares and exercises options

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

CYTOKINETICS INC executive Andrew Callos, EVP and Chief Commercial Officer, reported multiple stock option exercises and related share sales. On March 5, 2026, he exercised two non-qualified stock options covering 11,000 and 15,000 shares, converting them into common stock through derivative exercises.

He then completed two open-market sales of common stock totaling 26,000 shares, with 15,000 shares sold at $61.87 per share and 11,000 shares sold at $61.88 per share. After these transactions, he held 50,440 shares of common stock directly. The reported stock options vest over four years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months, subject to continued employment.

Insider Trade Summary

Net Seller: 26,000 shares ($1,608,730)

Net Sell 6 txns

Insider Callos Andrew

Role EVP, Chief Commercial Officer

Sold 26,000 shs ($1.61M)

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (Right to Buy)	11,000	$0.00	--
Exercise	Non-Qualified Stock Option (Right to Buy)	15,000	$0.00	--
Exercise	Common Stock	11,000	$39.13	$430K
Sale	Common Stock	15,000	$61.87	$928K
Sale	Common Stock	11,000	$61.88	$681K
Exercise	Common Stock	15,000	$23.26	$349K

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 24,403 shares (Direct); Common Stock — 76,440 shares (Direct)

Footnotes (1)

[object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/05/2026 - 04:27 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Callos Andrew

(Last)

(First)

(Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/05/2026		M		11,000	A	$39.13	76,440	D
Common Stock	03/05/2026		S		15,000	D	$61.87	61,440	D
Common Stock	03/05/2026		S		11,000	D	$61.88	50,440	D
Common Stock	03/05/2026		M		15,000	A	$23.26	65,440	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option (Right to Buy)	$39.13	03/05/2026		M			11,000	04/06/2023	03/06/2033	Common Stock	11,000	$0	24,403	D
Non-Qualified Stock Option (Right to Buy)	$23.26	03/05/2026		M			15,000	03/31/2022⁽¹⁾	03/31/2031	Common Stock	15,000	$0	69,000	D

Explanation of Responses:

1. Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Callos	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Andrew Callos report for CYTK?

Andrew Callos reported exercising non-qualified stock options and converting them into common stock, then selling 26,000 common shares in open-market transactions. These moves combined option exercises with partial share sales while retaining a significant remaining share position.

How many CYTOKINETICS (CYTK) shares did Andrew Callos sell and at what prices?

Andrew Callos sold a total of 26,000 CYTOKINETICS common shares. He sold 15,000 shares at $61.87 per share and 11,000 shares at $61.88 per share in open-market transactions reported for March 5, 2026.

How many CYTOKINETICS shares does Andrew Callos own after these transactions?

After the reported transactions, Andrew Callos directly holds 50,440 shares of CYTOKINETICS common stock. This figure reflects his position following the combination of stock option exercises and subsequent open-market sales disclosed in the Form 4 filing.

What type of stock options did Andrew Callos exercise at CYTOKINETICS (CYTK)?

He exercised non-qualified stock options, described as a right to buy CYTOKINETICS shares. The filing shows derivative exercises converting options into 11,000 and 15,000 common shares, consistent with standard executive equity compensation structures for long-term incentives.

What is the vesting schedule for Andrew Callos’s CYTOKINETICS stock options?

The stock options vest over four years from the grant date. One-quarter of the underlying shares vest on the one-year anniversary, and the remaining three-quarters vest monthly at 1/48 of the total over the next 36 months, subject to continued employment.

What is Andrew Callos’s role at CYTOKINETICS (CYTK)?

Andrew Callos serves as Executive Vice President and Chief Commercial Officer at CYTOKINETICS. His Form 4 filing reflects equity transactions related to this executive position, including non-qualified stock option exercises and open-market sales of common stock.